On 1 July 2026, AlzeCure Pharma AB (publ) (“AlzeCure”) announced that it has entered into an out-licensing and collaboration agreement with QuantumCell ApS, a Danish tech-enabled biotech company, regarding the global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856.

AlzeCure will receive a total upfront payment of USD 12 million, of which USD 5 million constitutes a direct investment in AlzeCure at a 30% premium to the 10-day average share price. The agreement further contains development and commercial milestone payments as well as tiered single-digit to low double-digit royalties on sales. The total deal value, excluding royalty payments, exceeds USD 2.2 billion.

ACD856 is a first-in-class small-molecule Trk-PAM drug candidate that has demonstrated cognitive enhancing, neuroprotective, anti-inflammatory and disease-modifying effects in preclinical models. The unique pharmacological mechanism enables multiple indications including Alzheimer’s disease, Parkinson’s disease and depression. The drug candidate is currently in clinical development.

ABG Sundal Collier is proud to have acted as financial advisor to AlzeCure in connection with this transaction and would like to congratulate AlzeCure on this important milestone.

* The transaction is subject to customary closing conditions, including approval by Swedish and Danish authorities under foreign direct investment regulations.